Literature DB >> 16470567

Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers.

Marc Marull1, Bertrand Rochat.   

Abstract

Imatinib (Gleevec) is an anticancer drug that inhibits specific protein kinases involved in cell proliferation. Whereas this drug is considered to have opened a new era, various mechanisms of resistance have been associated with imatinib relapse. Drug disposition in cancer cells including influx, efflux and drug metabolism is one mechanism that remains to be more thoroughly investigated. Moreover, recent genomic studies have revealed that some isozymes of cytochrome P450 (CYP) are possibly associated with the treatment outcome. Therefore, this research paper investigates the role of the activity of CYP1A1, 1A2, 1B1, 3A4, 4F2 and 4F3A/B on the fate of imatinib. First, a study of imatinib fragmentation was effected using electrospray triple-quadrupole and linear ion trap tandem mass spectrometers (MSn). Accurate mass determinations were performed at enhanced mass resolution for the identification of some product ions that were not predicted by two fragmentation softwares. Whereas the quadrupole MS was not designed for accurate mass measurement, delta mass errors were below 20 ppm. Then, a biotransformation study was effected in vitro. Imatinib metabolites were produced in microsomal incubations containing CYP isozymes. Imatinib and metabolites were extracted from incubation mixtures by protein precipitation, and supernatants were injected into a liquid chromatography equipment coupled with MS(n). Hydrophobic interaction liquid chromatography resolved one demethylated-, two hydroxy- and three N-oxide metabolites. Various rates of metabolite formation were observed between CYP isozymes. Liquid chromatography with deuterium oxide-containing mobile phase (H/D exchange) or incorporation of (18)O from H(2) (18)O added in the incubations was performed to elucidate the metabolite structure. Various MS(n) product scans (n < or = 4) were acquired on the linear ion trap or on the triple-quadrupole MS. Postulated structures of new metabolites are addressed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470567     DOI: 10.1002/jms.1002

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  8 in total

1.  Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

Authors:  A M Filppula; J Laitila; P J Neuvonen; J T Backman
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue.

Authors:  Dale S Cornett; Sara L Frappier; Richard M Caprioli
Journal:  Anal Chem       Date:  2008-06-20       Impact factor: 6.986

Review 3.  Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.

Authors:  Veerandra Kumar; Priyanka Singh; Sonu Kumar Gupta; Villayat Ali; Malkhey Verma
Journal:  Mol Cell Biochem       Date:  2022-02-07       Impact factor: 3.396

4.  CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.

Authors:  Henrik Gréen; Karin Skoglund; Franz Rommel; Rajaa A Mirghani; Kourosh Lotfi
Journal:  Eur J Clin Pharmacol       Date:  2010-04       Impact factor: 2.953

5.  The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

Authors:  Roos L Oostendorp; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2008-05-01       Impact factor: 3.850

6.  Metabolite Profiling in Anticancer Drug Development: A Systematic Review.

Authors:  Nadda Muhamad; Kesara Na-Bangchang
Journal:  Drug Des Devel Ther       Date:  2020-04-09       Impact factor: 4.162

7.  Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.

Authors:  Giovanni Martinelli; Ilaria Iacobucci; Simona Soverini; Francesca Palandri; Fausto Castagnetti; Gianantonio Rosti; Michele Baccarani
Journal:  Biologics       Date:  2007-06

8.  Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.

Authors:  Céline Narjoz; Amélie Favre; Justin McMullen; Philippe Kiehl; Michael Montemurro; William D Figg; Philippe Beaune; Isabelle de Waziers; Bertrand Rochat
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.